



## Momenta Pharmaceuticals Announces Date of First Quarter 2019 Financial Results Conference Call and Webcast

April 18, 2019

CAMBRIDGE, Mass., April 18, 2019 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will release its financial results for the first quarter ended March 31, 2019 before the U.S. financial markets open on Thursday, May 2, 2019.

Management will host a conference call on May 2, 2019 at 8:30 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 8949569. A live webcast of the call will be available on the "Investors" section of the company's website, [www.momentapharma.com](http://www.momentapharma.com). An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

### About Momenta

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta's product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hslgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta's wholly-owned proposed biosimilar to HUMIRA<sup>®</sup>, and M710, a proposed biosimilar to EYLEA<sup>®</sup> being developed in collaboration with Mylan. Momenta's two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa<sup>®</sup> (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.

To learn more about Momenta, please visit [www.momentapharma.com](http://www.momentapharma.com), which does not form a part of this press release.

Momenta's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

**Forward-Looking Statements** Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about the use efficacy, safety, tolerability, convenience and commercial potential of our product candidates, including their potential as best-in-class agents. Forward-looking statements may be identified by words such as "believe," "continue," "plan to", "potential," "will," and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including the risk of the unpredictable nature of early stage development efforts for our product candidates; safety, efficacy or tolerability problems with our product candidates; unexpected adverse clinical trial results; and those referred to under the section "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

### Contact:

Patty Eisenhaur  
Momenta Pharmaceuticals  
1-617-395-5189  
[IR@momentapharma.com](mailto:IR@momentapharma.com)

